Peptide Dosages InfoPeptide Dosages Info

Single Peptides

PNC-27 (30 mg Vial)

PNC-27 (30 mg Vial) Dosage Protocol Quickstart Highlights PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied…

Dose calculatorBack to Single Peptides
PNC-27 (30 mg Vial)

Quickstart Highlights

PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

  • Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.
  • Typical daily range: 100–500 mcg once daily (gradual titration).
  • Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
  • Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = 10 mg/mL)

Week Daily Dose (mcg) Units (per injection) (mL)
Weeks 1–2 100 mcg (0.10 mg) 1 unit (0.01 mL)
Weeks 3–4 200 mcg (0.20 mg) 2 units (0.02 mL)
Weeks 5–8 300 mcg (0.30 mg) 3 units (0.03 mL)
Weeks 9–12 400 mcg (0.40 mg) 4 units (0.04 mL)
Weeks 13–16 500 mcg (0.50 mg) 5 units (0.05 mL)

Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.

Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established[3]. Any dosing above a few hundred micrograms per day is purely speculative[4].

Reconstitution Steps

  1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
  2. Inject slowly down the vial wall; avoid foaming.
  3. Gently swirl/roll until dissolved (do not shake).
  4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

  • Peptide Vials (PNC-27, 30 mg each):
    • 8 weeks ≈ 1 vial (~15–20 mg total used)
    • 12 weeks ≈ 1 vial (~25 mg total used)
    • 16 weeks ≈ 2 vials (~35–40 mg total used)
  • Insulin Syringes (U‑100 or 30/50‑unit for precision):
    • Per week: 7 syringes (1/day)
    • 8 weeks: 56 syringes
    • 12 weeks: 84 syringes
    • 16 weeks: 112 syringes
  • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
    • 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
    • 12 weeks (1 vial): 3 mL → 1 × 10 mL bottle
    • 16 weeks (2 vials): 6 mL → 1 × 10 mL bottle
  • Alcohol Swabs: One for the vial stopper + one for the injection site each day.
    • Per week: 14 swabs (2/day)
    • 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
    • 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
    • 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily regimen.

  • Goal: Educational exploration of a p53‑derived peptide studied preclinically for selective cancer‑cell membrane disruption[1][2].
  • Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
  • Dose Range: 100–500 mcg daily with gradual titration.
  • Reconstitution: 3.0 mL per 30 mg vial (10 mg/mL) for simplified unit measurements.
  • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

  • Start: 100 mcg daily for 1–2 weeks; increase by ~100 mcg every 2 weeks as tolerated.
  • Target: 300–500 mcg daily by Weeks 5–16.
  • Frequency: Once per day (subcutaneous).
  • Cycle Length: 8–12 weeks; optional extension to 16 weeks.
  • Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality[5].

  • Lyophilized: Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; short‑term refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
  • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
  • Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

  • Use new sterile insulin syringes; dispose in a sharps container.
  • Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
  • Inject slowly; wait a few seconds before withdrawing the needle.
  • Document daily dose and site rotation to maintain consistency.
  • Regulatory Warning: PNC-27 has no FDA approval and no established human safety data[3]. This information is strictly educational.

How This Works

PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence[1]. Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells[2][6]. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration[4]. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.

Potential Benefits & Side Effects

Observations from preclinical literature only—no human data available.

  • Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 while sparing normal cells[2][6].
  • Mechanism involves direct membrane lysis rather than apoptosis in affected cells[7].
  • No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established[3].
  • Possible injection‑site reactions (redness, irritation) may occur with subcutaneous administration.

Lifestyle Factors

General supportive strategies (not specific to PNC-27).

  • Maintain a balanced, nutrient‑dense diet to support overall metabolic function.
  • Prioritize adequate sleep and stress management for immune and recovery support.
  • Consult qualified healthcare professionals before any experimental peptide use.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[8][9].

  • Clean the vial stopper and skin with alcohol; allow to dry.
  • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8].
  • Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
  • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[10].

Important Note

This content is for educational purposes only and is not medical advice. PNC-27 is an unapproved experimental compound with no established human safety or efficacy data[3].